Insights - Yesterday, both obesity and radiopharmaceuticals had year end catalysts that unfortunately did not meet investor expectations. Structure (GPCR) Weight Loss UpdateGPCR traded down 42% on … Continue Reading
Read NowInsights - Mural Oncology (MURA) is a recent spinout from Alkermes’ (ALKS) oncology division. MURA trades at a 78% discount to its cash balance. Yes, you read … Continue Reading
Premium: Read NowInsights - Medtronic called off its plans to buy EOFlow, a company making an insulin patch-pump that is embroiled in a patent dispute with Insulet (PODD). In May 2023, … Continue Reading
Premium: Read NowInsights - With Thanksgiving weekend here, food is atop the mind of all Americans. We thought it only appropriate to give an update on the obesity field. … Continue Reading
Read NowInsights - Structure Therapeutics (GPCR) is up more than 35% this morning after announcing Phase 1b data of its oral GLP-1 receptor agonist, GSBR-1290, in overweight patients. … Continue Reading
Read NowInsights - In a prior note, we shared how weight-loss drugs might impact obesity related markets. The hype craze has pushed additional data that is now being blown … Continue Reading
Read NowInsights - GLP-1, initially touted as a therapy for diabetes, have proven successful for weight loss, CV event reduction, and with beneficial effects in HFpEF. Weight is … Continue Reading
Read Now
